18-Nov-2026 11:15:26
ORCHPHARMAGeneral news
ORCHID PHARMA Q2 FY27 CONCALL: TARGETS 3–4 ADDITIONAL XBLYCEF LICENSING DEALS IN NEXT 2 QUARTERS; EXPECTS CEFIDEROCOL INDIA LAUNCH BY SEPTEMBER–OCTOBER 2027, 7ACA COMMERCIALIZATION BY MARCH 2027 & GROSS MARGINS ABOVE 35%
ORCHID PHARMA LIMITED